Patent cliffs aren’t just a legal event. They’re a pricing strategy.
If you want to understand how Big Pharma keeps revenue flowing after exclusivity ends, don’t start with the courtroom. Start with the pharmacy counter—and the fine print behind “refor…
Reformulated Drugs, Real Money: How Pharma Prices Its Way Past Patent Cliffs Read Post »
Drug pricing transparency is having a moment. Policymakers, payers, and patient advocates are rallying around the idea that if we simply shine a light on how drug prices are set—rebates, discounts, list prices, net prices, and the machinery in between—…
Drug Pricing Transparency Is More Dangerous Than Price Cuts Read Post »
Mark Cuban’s “cost-plus” pitch isn’t just a consumer-friendly pricing story. It’s a strategic threat model—one that big pharma has spent decades building defenses for, and one that policymakers and investors should be modeling now.
Here’s the agitation…
Pharma’s quiet superpower isn’t just R&D—it’s timing.
In the race to extend exclusivity, the winners aren’t always the ones with the most molecules. They’re the ones with the most precise calendars.
A new post from DrugPatentWatch lays out how phar…
How Pharma Companies Track IND/NDA Dates to Win Global Patent Extensions Read Post »
Pharma doesn’t “miss” patent windows. It tracks them.
The real question is how.
In a world where patent terms, regulatory exclusivities, and jurisdiction-specific rules can make or break a product’s commercial runway, the companies that win global exte…
How Pharma Companies Track IND/NDA Dates to Win Global Patent Extensions Read Post »
Europe’s “divisional patent” trap is one of those legal mechanisms that sounds technical—until you see what it does to patients, payers, and timelines.
Here’s the uncomfortable truth: Big Pharma can often delay generic entry without “losing in court.” …
Generic drugs are no longer “copy and paste.” They’re a precision engineering problem.
For years, the generics playbook was simple: file the paperwork, prove sameness, and move on. But the market has evolved—and so has the bar for approval. In today’…
Cracking Complex Generics: The Bioequivalence Playbook That Gets ANDAs Approved Read Post »
The Patent Clock Is Ticking—And the Best Talent Is Already in the Room
In pharma, the most valuable people don’t always announce themselves. They don’t need to. They’re already doing the work—drafting, prosecuting, negotiating, and stress-testing claim…
The Patent Clock: How to Find Pharma’s Best Talent Before They Know They’re Looking Read Post »
Pharma patent litigation is often described as a line item: legal fees, expert reports, court filings. But that’s the part you can see.
The real cost is the stuff that doesn’t show up neatly on an invoice—until it quietly changes the economics of a lau…
What Pharma Patent Litigation Actually Costs (It’s Not the Legal Bills) Read Post »
Australia’s “drug patent clock” sounds simple—until you watch it run.
In theory, patents are time-limited exclusivity. In practice, the clock can stretch, pause, restart, and—depending on how you measure it—end up meaning something very different for p…
Australia’s Drug Patent Clock: The Complete Guide to How Long Protection Actually Lasts Read Post »
Get new actionable insights and updates from BiotechBlog
